Area bioscience firm chasing vaccine raises $22 million

Tampa drugmaker also announced plans to redeem Series C preferred stock.

  • By Business Observer Staff
  • | 12:00 p.m. February 24, 2021
Courtesy. Oragenics President and CEO Alan Joslyn
Courtesy. Oragenics President and CEO Alan Joslyn
  • Tampa Bay-Lakeland
  • Share

TAMPA — Oragenics Inc. has raised $22 million through the sale of common stock and by exercising warrants on its common stock, the company says.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • April 1, 2026
Work starts on Naples apartments as developer secures $45M in financing
  • April 1, 2026
$300K Bradenton EDC contract up for vote in Manatee
  • April 1, 2026
27 Gulf Coast companies ranked among fastest growing in Southeast
  • April 1, 2026
Tampa tire store franchisor rolls into new brands, buys a restaurant

Sponsored Content